NCT00867230View on ClinicalTrials.gov

FTS Study in Patients With Advanced Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions
Myelodysplastic SyndromeLeukemia
Interventions
DRUG

FTS

Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.

Trial Locations (1)

77030

U.T.M.D. Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

Concordia Pharmaceuticals, Inc

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER